Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE-MC immunosuppression trial in virus-negative myocarditis or inflammatory cardiomyopathy
2024-517484-23-00Phase 4Authorised
- Sponsor
- Medical University of Warsaw
- Start
- Nov 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of prednisone and azathioprine in myocarditis and inflammatory cardiomyopathy (2 arms), sponsored by Medical University of Warsaw. Primary endpoint: LVEF at 12 months. Planned start Nov 2024; status: authorised.
02
Drugs
prednisoneazathioprine
03
Conditions
myocarditisinflammatory cardiomyopathy
Beyond the preview
Go deeper on 2024-517484-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517484-23-00.